The efficacy of immune checkpoint inhibitors following discontinuation for long‐term response or toxicity in advanced or metastatic non‐small‐cell lung cancers: A retrospective study

Documenti analoghi

• Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial
  di: Passildas Jahanmohan Judith, et al.
  Pubblicazione: (2024)
• Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
  di: Gen Lin, et al.
  Pubblicazione: (2024)
• Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
  di: Ayako Morita, et al.
  Pubblicazione: (2024)
• Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
  di: Jie Zhao, et al.
  Pubblicazione: (2024)
• Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer
  di: Shinkichi Takamori, et al.
  Pubblicazione: (2025)